Claims for Patent: 7,671,095

Summary for Patent: 7,671,095

Title:	Films and particles
Abstract:	Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses.
Inventor(s):	Colson; Yolonda (Needham, MA), Azouz; Solomon (San Antonio, TX), Grinstaff; Mark (Brookline, MA), Wolinsky; Jesse (Brookline, MA), Griset; Aaron (Brookline, MA)
Assignee:	The Trustees of the Boston University (Boston, MA) The Brigham and Women\'s Hospital, Inc. (Boston, MA)
Application Number:	11/756,587
Patent Claims:	1. An oligomer or polymer, represented by Formula XXXVIII: ##STR00085## wherein: Q' is independently selected from O, S, Se, and NH; G' is selected from ##STR00086## and R.sub.1'; R.sub.1' is selected from a straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, and fluorocarbon chain of 3-50 carbons, wherein each alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, or fluorocarbon chain is optionally substituted internally or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted amino, thiol, thioester, sulfate, phosphate, phosphonate, or halogen substituents; or R.sub.1' is selected from poly(ethylene glycol), poly(ethylene oxide), poly(hydroxyacid)), a carbohydrate, a protein, a polypeptide, an amino acid, a nucleic acid, a nucleotide, a polynucleotide, any DNA or RNA segment, a lipid, a polysaccharide, an antibody, a pharmaceutical agent, and any epitope for a biological receptor; or R.sub.1' is selected from a photocrosslinkable and an ionically crosslinkable group; x and y are each independently selected from an integer of 2-750; e is selected from an integer of 1-8; and each polymeric terminal group is selected from hydrogen, amines, thiols, amides, phosphates, sulphates, hydroxides, metals, alkanes, alkenes and alkynes. 2. The oligomer or polymer of claim 1, wherein R.sub.1' is selected from a straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, and fluorocarbon chain of 3-50 carbons, wherein each alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, or fluorocarbon chain is optionally substituted internally or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted amino, thiol, thioester, sulfate, phosphate, phosphonate, or halogen substituents. 3. The oligomer or polymer of claim 1, wherein R.sub.1' is selected from a straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, and fluorocarbon chain of 3-50 carbons. 4. The oligomer or polymer of claim 1, wherein R.sub.1' is a straight or branched alkyl chain of 3-50 carbons. 5. A polymeric film or particle comprising a polymer of claim 1. 6. A polymeric particle of claim 5, wherein the polymeric particle is a microparticle or nanoparticle. 7. A polymeric particle of claim 6, wherein the polymeric particle comprises a diameter of between about 1 nm and 2 microns. 8. A polymeric particle of claim 6, wherein the polymeric particle comprises a diameter between about 10 nm and 1 microns. 9. The polymeric film or particle of claim 5, further comprising an agent. 10. The polymeric film or particle of claim 9, wherein the agent is a biologically active agent comprising one or more of an anti-cancer, an anti-biotic, anti-neoplastic, an analgesic, an angiogenic, or agent that promotes healing. 11. The polymeric film or particle of claim 9, wherein the biologically active agent comprises one or more of asparaginase; bleomycin; busulfan; capecitabine; carboplatin; carmustine chlorambucil; cisplatin; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin; dexrazoxane; docetaxel; doxorubicin; etoposide; floxuridine; fludarabine; fluorouracil; gemcitabine; hydroxyurea; idarubicin; ifosfamide; irinotecan; lomustine; mechlorethamine; melphalan; mercaptopurine; methotrexate; mitomycin; mitotane; mitoxantrone; paclitaxel; premetrexed; pentostatin; plicamycin; procarbazine; rituximab; streptozocin; teniposide; thioguanine; thiotepa; vinblastine; vincristine; and vinorelbine. 12. A method of using the polymeric particle or film of claim 9, the method comprising applying the polymeric particle or film to one or more of the following: (i) a surgical resection margin, (ii) within a treated or untreated tumor or cavity, (iii) a target site of disease away from a surgical margin, and (iv) a lymph node. 13. The film of claim 9, wherein the film is a multi-layered film. 14. The film of claim 9, comprising a first layer comprising a first polymer of Formula XXXVIII, and a second layer comprising a second polymer different from Formula XXXVIII. 15. The film of claim 14, wherein the second polymer comprises one or more of poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), polycaprolactone, poly(trimethylene carbonate), polyester, polycarbonate, and polyamide. 16. The film of claim 9, wherein the film is a single layered film. 17. The oligomer or polymer of claim 1, wherein Q' is O. 18. The oligomer or polymer of claim 1, wherein G' is selected from: ##STR00087## 19. The oligomer or polymer of claim 1, wherein G' is: ##STR00088## 20. The oligomer or polymer of claim 1, wherein R.sub.1' is a straight or branched alkyl chain of 10 to 20 carbons. 21. The oligomer or polymer of claim 1, wherein R.sub.1' is selected from tetradecanyl, octadecanyl, octadec-9-enyl, 6-aminohexanyl, 6-hydroxyhexanyl, and 5-carboxypentanyl. 22. The oligomer or polymer of claim 1, having Formula XXXIX: ##STR00089## 23. The oligomer or polymer of claim 1, having Formula XL: ##STR00090## 24. The oligomer or polymer of claim 23, wherein G' is: ##STR00091## 25. The oligomer or polymer of claim 24, wherein R.sub.1' is a straight or branched alkyl chain of 3-50 carbons. 26. The oligomer or polymer of claim 24, wherein R.sub.1' is a straight or branched alkyl chain of 10 to 20 carbons. 27. The oligomer or polymer of claim 24, wherein R.sub.1' is selected from tetradecanyl, octadecanyl, octadec-9-enyl, 6-aminohexanyl, 6-hydroxyhexanyl, and 5-carboxypentanyl. 28. The oligomer or polymer of claim 1, wherein the oligomer or polymer is selected from: poly(myristic acid carbonate-co-.epsilon.-caprolactone); poly(stearic acid carbonate-co-.epsilon.-caprolactone); poly(oleic acid carbonate-co-.epsilon.-caprolactone); ##STR00092## 29. The oligomer or polymer of claim 1, which is poly(stearic acid carbonate-co-.epsilon.-caprolactone). 30. A polymeric film or particle, comprising an oligomer or polymer of claim 26. 31. A polymeric film or particle, comprising an oligomer or polymer of claim 29. 32. A method of using the polymeric particle or film of claim 30, the method comprising applying the polymeric particle or film to one or more of the following: (i) a surgical resection margin, (ii) within a treated or untreated tumor or cavity, (iii) a target site of disease away from a surgical margin, and (iv) a lymph node. 33. A method of using the polymeric particle or film of claim 31, the method comprising applying the polymeric particle or film to one or more of the following: (i) a surgical resection margin, (ii) within a treated or untreated tumor or cavity, (iii) a target site of disease away from a surgical margin, and (iv) a lymph node.

Details for Patent 7,671,095

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2026-05-31
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-05-31
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-05-31
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2026-05-31